Abstract
(a) Drug resistance (b) Tumor heterogeneity and collateral sensitivity Figure 1 : (a) General dynamical pattern of disease burden. It increases initially and then decreases as of the therapy starting point (t 0 ), and eventually rebounds after the maximum period with positive therapy effect (T max ). Relapse is found, at the earliest, when disease burden reaches detection threshold at t DT . (b) Change in composition of tumor cell population when a pair of collaterally sensitive drugs are given one after another.
Figure 2: Diagram of dynamics between sensitive cells population, C S , and resistant cells population, C R , (on the left panel) and the differential system of {C S , C R } (on the right panel) with s−proliferation rate of sensitive cells, r−proliferation rate of resistant cells, g−transition rate from C S to C R Figure 2 shows the diagrams of such population dynamics, and the system of ordinary differen- starts when it is much smaller than its carrying capacity which results in almost exponential growth.
101
C P has one and only one minimum point in {−∞, ∞}, after which C P increases monotonically. In summary, we assume that
116
• there is a pair of collaterally sensitive drugs, DrugA and DrugB, which are characterized 117 by their own model parameters, p A = {s A , r A , g A } and p B = {s B , r B , g B } respectively,
118
• cell population can be split into two subpopulations, A R -resistant to DrugA and at the same In addition to T max , another time point with significant meaning is T min , explained below. Since 135 the decreasing rate is almost zero around T max with no switch (see the black curve of Figure 5 
and 143 C P (t 1 given {s, r, g} = p B and {C
144
This comparison reveals that the two derivatives are equal at a specific point (this is T min , see the 145 yellow curve on Figure 6 ), the derivative of drug-switch is lower (higher in absolute value; higher 146 decreasing rate) if t 1 > T min (see the blue and green curves on Figure 6 ), and the derivative of 147 no-switch is lower if t 1 < T min (see the red curve on Figure 6 ).
149
T min depends on the parameters for the first drug {s 1 , r 1 , g 1 } and for the second drug {s 2 , r 2 },
150
and initial population ratio between resistant cells and sensitive cells for the first drug RpS 0 . Here,
151
transition parameter of second drug (g 2 ), and respective values of the two populations are unneces-
152
sary in the evaluation of T min , which is found to be
Figure 6: Comparison of total population curves with one-time drug-switch from DrugA to DrugB at different time points, (i) at < T min (worse than without-switch; red curve), (ii) at T min (same as without-switch; yellow curve), (iii) between T min and T max (better than without-switch; green curve), and (iv) T max (better than without-switch; blue curve). Each color of dot/curve represents cell population level on and after drug-switch of each switching strategy. The dashed curve mixed by yellow and black colors represent the yellow and black curves overlapped. Parameters:
An important issue observed in Figure 6 is that the population curve with only one-time drug-157 switch after T min (and before T max , assuming that T min < T max ) is not guaranteed to be lower 158 than that of one-time switch at T max over an entire time range. (i.e., the green curve relevant to the 159 switch at (T min + T max )/2 and the blue curve relevant to the switch at T max intersect at t ≈ 58 and 160 the blue curve is lower after the time of the intersection). However, sequential drug switches started 161 between T min and T max leave a possibility of finding a better drug schedule than the T max −based 162 strategy. Figure 7 shows possible choices of follow up switches (green and black curves) which 163 achieve better results than T max −switch (red curves), unlike the drug-switches started before T min 164 remaining less effective (magenta curve).
166
Optimal drug switch scheme will be discussed in detail in Section 4.2. The optimal scheduling 167 for the example of Figure 5 starts with the first drug until T min (blue curve for 0 < t ≤ T min )
168
followed by rapid exchange of the two drugs afterward (black curve for t > T min The difference between T min and T max (T gap ), provides intuition on how much shorter the first 179 drug administered than it is used to be.
180
T gap ({s 1 , r 1 , g 1 }, {s 2 , r 2 }) := T max ({s 1 , r 1 , g 1 },
We studied sensitivity analysis on T gap over a reasonable space of non-dimentionalized drug pa-181 rameters in Appendix B. Expectedly, as the proliferation rates under the second drugs increases
182
(r 2 ↑ and/or s 2 ↑), the optimal switching timing to the second drug is delayed (T min ↑ and T gap ↓).
183
As r 1 increases, both T min and T max decrease. However, T max decrease more than T min does, so in Ef (ApB) :
The effects of DrugA (specified by p A ) and DrugB (specified by p B ) defined in this way are equiv- at ApB = ApB * , and have no effect at ApB = −s A /r A (in case of DrugA) or ApB = −r B /s B (in case of DrugB). The drug effect is getting bigger, as ApB is getting farther from the no-effect level to the direction of getting less cell population resistant to the drug.
The population makeup changes in the opposite direction. As DrugA (or DrugB) therapy 212 continues, ApB continues to increase (or decrease). So, if DrugA (or DrugB) is given too 213 long, it should go through a period of no or almost no effect around ApB = −s A /r A (or around 214 ApB = −r B /s B ), but once the drug is switched after that, there will be a higher therapy effect with In this sections, we describe a drug-switch strategy to achieve the best effect possible with a pair of 226 collaterally sensitive drugs. It is numerically found, and consists of two stages.
227
• (Stage 1) to reach to the population makeup with balanced drug effect (ApB * ), so the period 228 lasts as long as T min of the first drug 229
• (Stage 2) to give the two drugs with a proper ratio in period (represented by k or k ; see Figure   230 9) in order to keep ApB being constant at ApB * , and switching them in a high frequency,
231
represented by ∆t ≈ 0
232
Figure 9: Diagram of the relationship between therapy duration (like ∆t, k ∆t, or ∆t/k ) and change in ApB around ApB * . ∆t represents an arbitrary time interval (supposed to be small, ∆t ≈ 0), and k represents a specific quantity corresponding to such ∆t and parameters of DrugA and DrugB. through DrugB therapy (∆t ), and finally (iii) taking ratio between the two therapy 237 periods (k = ∆t/∆t ). k depends on drug switch frequency and model parameters,
Such k is consistent with k , which is the ratio similarly evaluated with DrugB as first therapy and DrugA as follow-up therapy, in the optimal case of instantaneous switching,
We studied how sensitive k (Figure 11 (a) ). The time at which one of these events occurs is determined by an exponential 271 probability distribution, and we represent the algorithm as pseudo-code thus:
Step 2) Update from t to t + dt: 
We expanded the stochastic process for a single drug to treatment with two drugs being switched The emergence of resistance to our presently best therapies is a sad, and conserved reality in the 312 oncology clinics today. While much effort has been put into novel drug discovery to combat this,
313
there is also a growing interest in determining optimal sequences, or cycles of drugs that induce 314
13
. continued (or collateral) sensitivity. To study this second scenario, we proposed a simple dynami-315 cal systems model of tumor evolution in a heterogeneous tumor composed of two cell phenotypes.
316
While in reality, cell phenotype can be defined in many ways, here we completely describe it by 317 considering only sensitivity (or resistance) to a pair of collaterally sensitive drugs, which is en-318 coded in their differential growth rates in specific conditions. While the resulting mathematical 319 model conveys only simple, but essential, features of cell population dynamics, it does yield ana-320 lytical solutions that more complex models can not.
322
Our original motivation was to consider more complicated sequences, or cycles of drug therapy, 323 however, the model presented herein is difficult to apply for an expanded system of more than two 324 drugs. On the other hand, the cell classification used by other [11, 12, 21, 22, 25] considers sen-325 sitivity and resistance independently, or even specifically to a given, abstracted, genotype [26, 27] .
326
Therefore, in case of 2 drugs, there are 2 2 = 4 groups, (i) sensitive to both drugs, (ii) and (iii) 327 resistant to only one drug, and (iv) resistant to both drugs. This formulation could be expanded and 328 applied to more than two drugs [11, 25] , and we will consider it in future work.
330
The simplicity of our exponential growth/decay model is owing to the assumption of a constant birth and death rate (as opposed to the net growth rate) caused extinction earlier in time ( Figure   365 12, Figure 13 ). This can be explained by the fact that extinction is the only absorbing state in our 366 model, and therefore higher death rates determine when extinction occurs, even when birth rates 367 are also higher. Our stochastic model therefore suggests that highly cytotoxic drugs (even those 368 with correspondingly minimal cytostatic effects) are more effective at eliminating tumors, at least 369 when the tumor population is small. opportunities to improve our understanding and treatment of drug resistance, and also future op-383 portunities for new modelling endeavors.
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Appendix A Derivations of explicit expressions
for any positive integer, n, and for all
Then, we need to prove that F (n) = L for n = 1, 2, 3, ...
for any positive integer, n, and
(by Proposition A.3 and Lemma A.5)
The equality is true for n = 1
If n ≥ 2, and the equality works for all integers 1 ≤ m ≤ n − 1,
(by the inductive assumption and Proposition A.3 and Lemma A.5)
The equality is true for n ≥ 2) Therefore, proved.
508
Theorem A.8. If Drug A and Drug B are prescribed in turn with relative intensity f and 1 − f ,
509
and are switched instantaneously, V obeys
Proof. For any time point t 0 , let us define V (t) as a vector-valued function of A R (t) and B R (t) describing cell population dynamics under periodic therapy started on t 0 with DrugA assigned on t 0 +m ≤ t < t 0 +(m+f ) and DrugB on t 0 +(m+f ) ≤ t < t 0 +(m+1) for m = 0, 1, 2, 3, .... Then, by Proposition A.1 and the definitions of A and B,
where
. And, V 0 (t) represents instantaneous drug switch.
For any ∆t > 0 and any positive integer n, there exists = (n, ∆t) such that
20
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For such ∆t, n and (n, ∆t), V (t 0 + ∆t) is bounded, since local extrema can occur only at which drugs switch by Proposition A.2. That is,
And,
Similar to (*4),
By (*4) -(*6),
Then, by (*3), (*7) and the squeeze theorem,
Therefore,
A.2 Population dynamics with the optimal regimen 517 Lemma A.9.
518 ApB * and f * from (8), (10) and (13).
519
Proof. Let
where U = 1 −ApB * along with 
is an eigenvector of D * with the corresponding eigenvalue, λ. Then, 532 the solution of (*2) with the initial value (*1) is If ApB(0) < ApB * , T gap ({s 1 , r 1 }, {s 2 , r 2 }) :=
23
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In general, cells mutate in a slower way than they proliferate (ref), so we ran sensitivity analysis on T gap for all a 1 for a ∈ {−s 1 , −s 2 , r 1 , r 2 }. Figure 14 shows T gap over the range of 20 ≤
553
−s 1 , −s 2 , r 1 , r 2 ≤ 100. So, under the assumption that g 1 min{−s 1 , −s 2 , r 1 , r 2 },
554
T gap ({s 1 , r 1 }, {s 2 , r 2 }) ≈
which approximate the contour curves of Figure 14 .
557
Figure 14: Contour maps of T gap over ranges of 20 ≤ a ≤ 100 for a ∈ {−s 1 , −s 2 , r 1 , r 2 } and r 1 r 2 < s 1 s 2 (Condition (6))
Regarding the regulated intensities among the two drugs, k * , we assumed that g 1 ≈ g 2 := g, 558 similarly assuming that they are both much smaller than {−s 1 , −s 2 , r 1 , r 2 }. 
In sensitivity analysis, we use
which represents intensity fraction of initially better drug out of total therapy. We evaluated f * 564 over the same ranges of {s 1 , s 2 , r 1 , r 2 } like the previous exercise. (see Figure 15) Figure 15 : Contour maps of f * over ranges of 20 ≤ a ≤ 100 for a ∈ {−s 1 , −s 2 , r 1 , r 2 } and r 1 r 2 < s 1 s 2 (Condition (6))
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569
In clinical practice, the instantaneous drug-switch which is proposed in this research to apply in the 570 second stage of the optimal control is not implementable. Therefore, we studied similar schedules 571 to the optimal case, and compared the therapy effects between the different schedules of admin-572 istrations. In the "similar" schedules, the first stage with an initial drug remained same to the 573 optimal schedule, but the second part of instantaneous switch (with ∆t = 0) has been modified 574 into fast switch (∆t 0). Figure 16 shows how the effect on population with instantaneous switch 575 (∆t = 0)and fast switches (multiple choices of ∆t 0) are different for a choice of drug parameter 576 values. Expectedly, the smaller ∆t is chosen, the closer to the ideal case of therapy effect. And, 577 a choice of reasonably small ∆t (like 1 day or 3 days) results in the outcome quite close to the 578 optimal scenario.
580
We simulated same exercise with k * (from (10)) instead of k(∆t) modulated by ∆t ( Figure   581 17). Only invisibly small differences has been observed between Figure 16 and Figure 17 , which 582 justifies general usage of k * independent from ∆t. 
Appendix D Stochastic simulation codes

585
The computational code written in Python will be provided at Github (https://github.com/nryoon12/Optimal- 
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